A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution
administered to patients with HIV infection. To evaluate the potential anti-HIV activity of
TCDO.